31948-87-5

Basic information

• Product Name: 3-BROMO-5-IODOANILINE
• Synonyms: 3-BROMO-5-IODOANILINE;BENZENAMINE, 3-BROMO-5-IODO-;3-Bromo-5-iodo-phenylamine
• CAS NO: 31948-87-5
• Molecular Formula: C₆H₅BrIN
• Molecular Weight: 297.92
• Mol File: 31948-87-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 335.486°C at 760 mmHg
• Flash Point: 156.696°C
• Appearance: /
• Density: 2.292g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.715
• PKA: 2.56±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-5-IODOANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-IODOANILINE(31948-87-5)
• EPA Substance Registry System: 3-BROMO-5-IODOANILINE(31948-87-5)

Safety Data

• Hazardous Substances Data: 31948-87-5(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-iodoaniline is a chemical compound that falls under the category of aromatic amines. It is comprised of a benzene ring with an amino group and two halogen atoms, bromine and iodine, attached to the ring. 3-BROMO-5-IODOANILINE is commonly used in organic synthesis and pharmaceutical research, as well as in the production of dyes and other organic chemicals. It is known for its high reactivity and is a key building block in the synthesis of various biologically active compounds. Additionally, it can be used in the production of agrochemicals and in the manufacturing of specialty chemicals. However, it is important to handle this compound with care, as it is hazardous if not properly managed.

InChI:InChI=1/C6H5BrIN/c7-4-1-5(8)3-6(9)2-4/h1-3H,9H2

Upstream product

• 861601-15-2 1-bromo-3-iodo-5-nitrobenzene 
• 915413-42-2 (3-bromo-5-iodophenyl)carbamic acid tert-butyl ester 
• 915413-41-1 3-bromo-5-iodobenzoylazide 
• 188815-32-9 3-bromo-5-iodo-benzoic acid 
• 875-51-4 4-Bromo-2-nitroaniline 

Downstream Products

• 1000289-32-6 1-benzoyl-3-(3-bromo-5-iodophenyl)thiourea 
• 915413-54-6 N-(3-bromo-5-(6-methoxypyridin-3-yl)phenyl)acetamide 
• 1260030-06-5 N-(3-bromo-5-(pyridin-4-yl)phenyl)methanesulfonamide 
• 1260030-07-6 C₃₁H₃₉N₃O₂Si 
• 915413-46-6 N-(3-bromo-5-iodophenyl)acetamide 
• 915413-50-2 N-(3-bromo-5-iodophenyl)methanesulfonamide 
• 1000289-33-7 (3-bromo-5-iodophenyl)thiourea 
• 62606-00-2 3-bromo-5-(methylsulfonyl)aniline 
• 62606-01-3 3-iodo-5-(methylsulfonyl)aniline 
• 915413-44-4 (3-bromo-5-pyridin-3-yl-phenyl)-carbamic acid methyl ester 
• 915413-43-3 (3-bromo-5-iodo-phenyl)-carbamic acid methyl ester 

Relevant articles and documents

Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Aldo-keto reductase 1C3 (AKR1C3) catalyzes the synthesis of 9α,11β-prostaglandin (PG) F2α and PGF2α prostanoids that sustain the growth of myeloid precursors in the bone marrow. The enzyme is overexpressed in acute myeloid leukemia (

Synthesis and pharmacological evaluation of N -(3-(1 H -Indol-4-yl)-5-(2- methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent

The synthesis and optimization of a series of orally bioavailable 1-(1H-indol-4-yl)-3,5-disubstituted benzene analogues as antimitotic agents are described. A functionalized dibromobenzene intermediate was used as a key scaffold, which when modified by sequential Suzuki coupling and Buchwald-Hartwig amination provided a flexible entry to 1,3,5-trisubstituted phenyl compounds. A 1H-indol-4-yl moiety at the 1-position was determined to be a critical feature for optimal potency. The compounds have been shown to induce cell cycle arrest at the G2/M phase and demonstrate efficacy in both cell viability and cell proliferation assays. The primary site of action for these agents is revealed by their colchicine competitive inhibition of tubulin polymerization, and a computational model has been developed for the association of these compounds to tubulin. An optimized lead LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model.

ANTI-CANCER AGENTS ANS USES THEREOF

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula (I): and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3 R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6- 10 carbons in the ring portion, an optionally-substituted 6- membered heteroaryl group having 1- 3 nitrogen atoms in the ring portion, an optionally-substituted 5- membered heteroaryl group having 0- 4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6- membered ring is fused either to a 5- membered ring or to a 6- membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.